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not reﬂect the actual level of utilization and need to be
completed with alternative methods of data collection.
PHP3
IMPROVING PATIENT ACCESS TO
INNOVATION—THE NEW BELGIAN
REIMBURSEMENT PROCEDURE
Umbach I, Quaetaert M,Vannecke C, Dewitte M,
Ravelingien I,Verpooten G, Tomas M
NIHISB, Brussels, Belgium
OBJECTIVES: Belgium has implemented since January
2002 a new reimbursement structure—the Commission
for the Reimbursement of Medicines (CRM). One of the
objectives is to improve time taken between the granting
of a marketing authorisation and pricing/reimbursement
decisions in full consistency with the European Commu-
nity legislation. METHODS: The CRM is responsible for
both clinical and economic evaluation of the submissions.
The decision relating to the admission of a specialty to
the list of reimbursed products is taken after evaluation
of several criteria: therapeutic value, price and basis for
reimbursement, therapeutic and social needs, budget
impact and cost-effectiveness. With regard to the thera-
peutic value, three classes have been deﬁned: class 1)
demonstrated added value; class 2) no added value; and
class 3) generic drugs. For an independent evaluation of
the dossiers the NIHISB has appointed a team of internal
experts. They provide evaluation reports within 60 days
and a reimburserment proposal within 150 days, to be
endorsed by the CRM. Guidelines have been developed
to assist applicants in preparing their submissions.
RESULTS: From January 1st to June 1st, 2002, 219
dossiers have been submitted to the CRM. Seventy-one
evaluation reports were issued during the same period
and timeline compliance was >90%. CONCLUSIONS:
After ﬁve months of CRM functioning, the timelines are
respected and a large majority of the evaluation reports
produced by the internal experts were endorsed. The
main challenges for the future will be to keep trans-
parency and consistency in the decisions taken, to respect
the short deadlines, to maintain the independence of mind
of the experts, and to continue to evaluate sequentially
the scientiﬁc and ﬁnancial aspects in the decision making
process.
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OUT-OF-POCKET PAYMENT IN BELGIUM:AN
ANALYSIS IN RELATION TO PATHOLOGY
Ooms D, Puttevils D,Wissels G, Koen P, Dirk C,
Beeckmans J
Free University Brussels, Brussels, Belgium
OBJECTIVES: Although mainly ﬁnanced by public
resources, Belgian patients are in most cases bound to pay
a contribution for medical acts and services described in
a very precise nomenclature. In order to lower the burden
of health care costs, the minister of social affairs recently
restricted this patients’ contribution to a maximum
(regarding the nomenclature and lump sum fees), accord-
ing to the ﬁnancial resources of the beneﬁciary. The goal
of this study is to detect elements that force the level out-
of-pocket payment up so that government actions can
take these results into account. METHODS: A represen-
tative sample of 30 acute hospitals (277.521 inpatient
stays) related to data on utilisation of resources and data
concerning the pathology, was withdrawn from national
databank (1996). Using descriptive statistics the patients’
contributions were mapped. Patients with high personal
contributions were selected and analysed. RESULTS:
On average 17% of the total invoice for a hospital stay
is paid by the patients’ own resources (€198,79). This
amount consists of lump sum fees (60,1%), either paid
per admission (medical imaging, technical procedures,
etc.) or depending on the length of stay, not reimbursed
drugs (14,4%), medical acts and services as described in
the nomenclature (11,3%), supplements for medical
devices (7,4%), various costs (6,7%) and clinical biology
(0,1%). Certain patients groups, depending on the
pathology, bear a signiﬁcant larger personal contribution.
CONCLUSIONS: The “maximum invoice” does not fully
cover all out-of-pocket payments. These ﬁndings may
lead to further discussion considering criteria for the
“maximum invoice”.
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Pirk O, Rosenfeld S, Hass B, Fricke FU
Fricke & Pirk GmbH, Nuremberg, Germany
OBJECTIVE: According to a law recently enacted in
Germany “aut idem” is an imprint on the prescription
obliging the pharmacist to give the patient a drug out of
a group of its cheapest generic versions, unless the physi-
cian excludes this by marking “nec aut idem” on the 
prescription. In view of the Statuary Health Insurance
spendings on pharmaceuticals the Ministry of Health thus
intends to achieve savings of €250 million p. a. but doubts
are manifold. To analyse the efﬁciency of “aut idem” a
model calculation was made for epilepsy treatment.
METHOD: In a decision tree model the costs of “aut
idem” versus “nec aut idem” prescription of Carba-
mazepin were calculated. “Nec aut idem” brings no
change for the patient whereas “aut idem” effects a drug
switch with multiple risks for the patients. On the basis
of up-to-date literature and ofﬁcial data sources assump-
tions were made on the reduction of drug efﬁcacy due to
modiﬁed bioavailability, a risk for 15% of the patients,
with additional ﬁts leading to an increase in treatment
expenses of which only the costs for the patients’ 
social health insurance were taken into consideration.
RESULTS: The What-if-analysis gives proof that in the
ratio of €114,93 to €56,18 “aut idem” is more expensive
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than “nec aut idem” per patient and quarter year. The
sensitivity analysis shows that “aut idem” will only lead
to cost savings if more than 92% of the pharmacists
inform the practitioners about the substitution and they
consequently check the medication. CONCLUSION:
With a conservative estimate of 150,000 patients in
Germany suffering from epilepsy and treated with 
Carbamazepin “aut idem” could lead to an increase in
expenses of €36 million p. a. Taking into account that
there are another 16 indications such as diabetes and
cardiac diseases which “aut idem” could also bring addi-
tional expenses about the cost saving effect of “aut idem”
is truly to be doubted.
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DRUG COSTS REGULATION SYSTEM IN THE
SLOVAK REPUBLIC
Tomek D
Health Insurance Fund APOLLO, Bratislava, Slovak Republic
OBJECTIVES: During last decade Slovakia has been
undergoing a transformation of its economy and the
health care has also been completely changed. A system
of health insurance had to be created and regulation tools
to restrain growing expenditures, especially drug costs,
had to be introduced. Nowadays one of the most devel-
oped tools is reimbursement scheme based on ATC
(anatomic, therapeutic and chemical classiﬁcation of
WHO) & DDD (deﬁned-daily dose) classiﬁcation. The
substance of this system and ﬁnancial impact of 
reimbursement reviews are to be presented herein.
METHODS: Mathematical modeling of current costs and
expected costs were applied. Impact of non-quantitative
reimbursement changes aimed at rationalizing of pre-
scription were also analyzed. All calculations were made
on the basis of health insurance data regarding drug 
consumption compulsorily reported to the Ministry of
Health. RESULTS: Due to reimbursement review, differ-
ence between the drug costs trends (assuming constant
reimbursement levels) and actual costs (reimbursement
changes are included) for the period of 1996 through
2002 stands for approximately SKK 3.9 billion. This
ﬁgure represents the savings of health insurance funds,
which can be used for other purposes. CONCLUSIONS:
Drug costs monitoring system, through obligatory reports
of health insurance companies to the Ministry of Health,
together with reimbursement level set per one DDD of
drug enable us to inﬂuence drug costs through reim-
bursement reviews. Nowadays some steps to equalize the
reimbursement levels of different active substances are
being taken and large database analysis are in progress.
It should also be emphasized that all countries are con-
fronted with health costs increase regardless of their level
of economic development. They are creating their own
system of dealing with drug containment. In order to
facilitate the development of most effective regulation






THE DEVELOPMENT OF CLINICAL PRACTICE
GUIDELINES:A SURVEY OF 38 GUIDELINES IN
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OBJECTIVES: To examine the types and roles of models
for economic evaluations in support of clinical practice
guidelines development in the Netherlands. METHODS:
The guideline development process for 38 recent treat-
ment guidelines was surveyed to study the economic eval-
uations performed during their development, starting in
1998. To this end, a standardised questionnaire was com-
pleted by those participants who performed the economic
evaluation. Since one goal of this study was to examine
how models were used in the economic evaluation
process, each respondent was asked a series of questions
relating to the use of modelling as part of the economic
evaluation activities. RESULTS: The most common type
of patient management issue involved treatment (19 of
38, 50%), followed by prevention (8, 21%), diagnosis (6,
16%), screening (4, 11%) and care (1, 3%). Despite this
variation, a limited selection of model types was used:
Markov model (11, 29%), decision analysis (9, 24%),
micro-simulation (8, 21%), other types (5, 13%), and no
model (5, 13%). The purpose of most Markov models
(10/11) was to extrapolate research results, while the
purpose of decision models often varied. Existing models
such as the Eastman diabetes model were often used
(18/38, 47%) although new models were frequently
created (15/38, 40%). CONCLUSIONS: During the
development of clinical practice guidelines, models are
often used to assist in economic evaluation. While the
purpose of a model is associated with model type, the
choice of model also depends on the experience in 
the ﬁeld and the speciﬁc question at hand. As well, the
frequent uniqueness of the issues faced for a given guide-
line means that new models are often developed. A tax-
onomy based on function is advised. Acceptance of 
the model results among clinicians was almost 100%,
however this is partly explained by the iterative nature of
guidelines development.
